Clinical And Regulatory RiskClinical trial failures or equivocal data could significantly impact the stock, as well as the inability to secure regulatory approval for key products such as VAR 200 or IC 100.
Financial Valuation RiskAn increase in the discount rate used in the rNPV model to 18% reflects growing concerns about the company's financial stability and could lead to a lower valuation of the stock.
Funding And Trial RiskA chronic lack of funding raises concerns that clinical trials might be underpowered, potentially leading to less conclusive results and negatively affecting the stock.